 Ubiquitin-Protein Ligases
"Ubiquitin-Protein Ligases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes.
| Descriptor ID |
D044767
|
| MeSH Number(s) |
D08.811.464.938.750
|
| Concept/Terms |
Ubiquitin-Protein Ligases- Ubiquitin-Protein Ligases
- Ligases, Ubiquitin-Protein
- Ubiquitin Protein Ligases
- Ubiquitin-Protein Ligase E3
- Ligase E3, Ubiquitin-Protein
- Ubiquitin Protein Ligase E3
- Ubiquitin Ligase E3
- E3, Ubiquitin Ligase
- Ligase E3, Ubiquitin
- Ubiquitin-Protein Ligase
- Ligase, Ubiquitin-Protein
- Ubiquitin Protein Ligase
- E3 Ligase
- Ligase, E3
- E3 Ubiquitin Ligase
- Ligase, E3 Ubiquitin
- Ubiquitin Ligase, E3
|
Below are MeSH descriptors whose meaning is more general than "Ubiquitin-Protein Ligases".
Below are MeSH descriptors whose meaning is more specific than "Ubiquitin-Protein Ligases".
This graph shows the total number of publications written about "Ubiquitin-Protein Ligases" by people in UAMS Profiles by year, and whether "Ubiquitin-Protein Ligases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 3 | 2 | 5 | | 2023 | 1 | 2 | 3 | | 2022 | 1 | 0 | 1 | | 2021 | 3 | 1 | 4 | | 2020 | 4 | 5 | 9 | | 2019 | 2 | 4 | 6 | | 2018 | 0 | 2 | 2 | | 2017 | 2 | 4 | 6 | | 2016 | 0 | 3 | 3 | | 2013 | 1 | 1 | 2 | | 2011 | 2 | 1 | 3 | | 2010 | 2 | 2 | 4 | | 2009 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2007 | 2 | 1 | 3 | | 2006 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Ubiquitin-Protein Ligases" by people in Profiles over the past ten years.
-
Salunkhe S, Daley JM, Kaur H, Tomimatsu N, Xue C, Raina VB, Jasper AM, Rogers CM, Li W, Zhou S, Mojidra R, Kwon Y, Fang Q, Ji JH, Badamchi Shabestari A, Fitzgerald O, Dinh H, Mukherjee B, Habib AA, Hromas R, Mazin AV, Wasmuth EV, Olsen SK, Libich DS, Zhou D, Zhao W, Greene EC, Burma S, Sung P. Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination. Nature. 2024 Oct; 634(8033):482-491.
-
Xiao Y, Yuan Y, Liu Y, Lin Z, Zheng G, Zhou D, Lv D. Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. J Med Chem. 2024 Jul 25; 67(14):11580-11596.
-
Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):762-769.
-
Kelliher JL, Folkerts ML, Shen KV, Song W, Tengler K, Stiefel CM, Lee SO, Dray E, Zhao W, Koss B, Pannunzio NR, Leung JW. Evolved histone tail regulates 53BP1 recruitment at damaged chromatin. Nat Commun. 2024 May 31; 15(1):4634.
-
Espejo-Serrano C, Aitken C, Tan BF, May DG, Chrisopulos RJ, Roux KJ, Demmers JA, Mackintosh SG, Gribnau J, Bustos F, Gontan C, Findlay GM. Chromatin targeting of the RNF12/RLIM E3 ubiquitin ligase controls transcriptional responses. Life Sci Alliance. 2024 03; 7(3).
-
Lee SO, Kelliher JL, Song W, Tengler K, Sarkar A, Dray E, Leung JWC. UBA80 and UBA52 fine-tune RNF168-dependent histone ubiquitination and DNA repair. J Biol Chem. 2023 08; 299(8):105043.
-
Ma N, Li N, Yu Z, Chen C, Zhou DX, Zhao Y. The F-box protein SHORT PRIMARY ROOT modulates primary root meristem activity by targeting SEUSS-LIKE protein for degradation in rice. J Integr Plant Biol. 2023 Aug; 65(8):1937-1949.
-
AlAbdi L, Desbois M, Rusnac DV, Sulaiman RA, Rosenfeld JA, Lalani S, Murdock DR, Burrage LC, Billie Au PY, Towner S, Wilson WG, Wong L, Brunet T, Strobl-Wildemann G, Burton JE, Hoganson G, McWalter K, Begtrup A, Zarate YA, Christensen EL, Opperman KJ, Giles AC, Helaby R, Kania A, Zheng N, Grill B, Alkuraya FS. Loss-of-function variants in MYCBP2 cause neurobehavioural phenotypes and corpus callosum defects. Brain. 2023 04 19; 146(4):1373-1387.
-
Pei J, Xiao Y, Liu X, Hu W, Sobh A, Yuan Y, Zhou S, Hua N, Mackintosh SG, Zhang X, Basso KB, Kamat M, Yang Q, Licht JD, Zheng G, Zhou D, Lv D. Piperlongumine conjugates induce targeted protein degradation. Cell Chem Biol. 2023 02 16; 30(2):203-213.e17.
-
Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, Tsai YH, Uryu H, Shen Y, Byrum SD, Edmondson RD, Mackintosh SG, Cai L, Liu Z, Aggarwal AK, Tackett AJ, Liu J, Jin J, Wang GG. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022 06; 41(24):3328-3340.
-
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.
-
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fern?ndez RA, Bittrich M, Ruiz-Heredia Y, Da Vi? M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, St?hmer T, Chatterjee M, Kull M, Kr?nke J, Agirre X, Martin-Subero JI, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kort?m KM. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021 11 04; 138(18):1721-1726.
-
Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li HY, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Adv Sci (Weinh). 2021 10; 8(20):e2102555.
-
Jones JR, Barber A, Le Bihan YV, Weinhold N, Ashby C, Walker BA, Wardell CP, Wang H, Kaiser MF, Jackson GH, Davies FE, Chopra R, Morgan GJ, Pawlyn C. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia. 2021 10; 35(10):3017-3020.
-
Kelliher J, Ghosal G, Leung JWC. New answers to the old RIDDLE: RNF168 and the DNA damage response pathway. FEBS J. 2022 05; 289(9):2467-2480.
-
Parra O, Bridge JA, Busam KJ, Shalin SC, Linos K. Dermal melanocytic tumor with CRTC1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity. J Cutan Pathol. 2021 Jul; 48(7):915-924.
-
Gu C, Lu T, Wang W, Shao M, Wei R, Guo M, Li R, Qiao L, Hu Y, Zhan F, Seckinger A, Hose D, Yang Y. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia. 2021 06; 35(6):1803-1807.
-
Samanta D. Epilepsy in Angelman syndrome: A scoping review. Brain Dev. 2021 Jan; 43(1):32-44.
-
He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol. 2020 07 27; 13(1):103.
-
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 07 16; 13(1):95.
-
Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene. 2020 06; 39(26):4909-4924.
-
Kelliher JL, West KL, Gong Q, Leung JWC. Histone H2A variants alpha1-extension helix directs RNF168-mediated ubiquitination. Nat Commun. 2020 05 18; 11(1):2462.
-
Zhang X, He Y, Zhang P, Budamagunta V, Lv D, Thummuri D, Yang Y, Pei J, Yuan Y, Zhou D, Zheng G. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 01; 199:112397.
-
He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, Khan S, Liu X, Zhang X, Lv D, Song L, Li W, Thummuri D, Yuan Y, Wiegand JS, Ortiz YT, Budamagunta V, Elisseeff JH, Campisi J, Almeida M, Zheng G, Zhou D. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020 04 24; 11(1):1996.
-
Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clin Cancer Res. 2020 07 15; 26(14):3881-3888.
-
Balasubramaniam M, Parcon PA, Bose C, Liu L, Jones RA, Farlow MR, Mrak RE, Barger SW, Griffin WST. Interleukin-1? drives NEDD8 nuclear-to-cytoplasmic translocation, fostering parkin activation via NEDD8 binding to the P-ubiquitin activating site. J Neuroinflammation. 2019 Dec 27; 16(1):275.
-
Zhang X, Thummuri D, He Y, Liu X, Zhang P, Zhou D, Zheng G. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun (Camb). 2019 Dec 05; 55(98):14765-14768.
-
Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Vi? MD, Sanchez R, Bruins L, Demler T, M?ller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, St?hmer T, Kort?m KM. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020 05; 105(5):e237-e241.
-
Moro T, Brightwell CR, Phalen DE, McKenna CF, Lane SJ, Porter C, Volpi E, Rasmussen BB, Fry CS. Low skeletal muscle capillarization limits muscle adaptation to resistance exercise training in older adults. Exp Gerontol. 2019 11; 127:110723.
-
Patil A, Manzano M, Gottwein E. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Blood Adv. 2019 07 23; 3(14):2105-2117.
-
Cho JJ, Xu Z, Parthasarathy U, Drashansky TT, Helm EY, Zuniga AN, Lorentsen KJ, Mansouri S, Cho JY, Edelmann MJ, Duong DM, Gehring T, Seeholzer T, Krappmann D, Uddin MN, Califano D, Wang RL, Jin L, Li H, Lv D, Zhou D, Zhou L, Avram D. Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. Nat Commun. 2019 02 11; 10(1):701.
-
Chen Y, Hou Y, Yang J, Du R, Chen C, Chen F, Wang H, Ge R, Chen J. P75 Involved in the Ubiquitination of a-synuclein in Rotenone-based Parkinson's Disease Models. Neuroscience. 2018 09 15; 388:367-373.
-
Patil A, Manzano M, Gottwein E. CK1a and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018 08 09; 132(6):577-586.
-
Rahmatallah Y, Khaidakov M, Lai KK, Goyne HE, Lamps LW, Hagedorn CH, Glazko G. Platform-independent gene expression signature differentiates sessile serrated adenomas/polyps and hyperplastic polyps of the colon. BMC Med Genomics. 2017 12 28; 10(1):81.
-
Wang P, Byrum S, Fowler FC, Pal S, Tackett AJ, Tyler JK. Proteomic identification of histone post-translational modifications and proteins enriched at a DNA double-strand break. Nucleic Acids Res. 2017 Nov 02; 45(19):10923-10940.
-
Naumov A, Kratzer S, Ting LM, Kim K, Suvorova ES, White MW. The Toxoplasma Centrocone Houses Cell Cycle Regulatory Factors. mBio. 2017 08 22; 8(4).
-
Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget. 2017 Apr 25; 8(17):27854-27867.
-
Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI, Bellido T. Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases. Endocrinology. 2017 03 01; 158(3):664-677.
-
Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017 02 24; 7(2):e535.
-
Gulia R, Sharma R, Bhattacharyya S. A Critical Role for Ubiquitination in the Endocytosis of Glutamate Receptors. J Biol Chem. 2017 01 27; 292(4):1426-1437.
-
Mitchell JS, Li N, Weinhold N, F?rsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, J?ud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, N?then MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 07 01; 7:12050.
-
Pryde KR, Smith HL, Chau KY, Schapira AH. PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. J Cell Biol. 2016 04 25; 213(2):163-71.
-
O'Connor HF, Lyon N, Leung JW, Agarwal P, Swaim CD, Miller KM, Huibregtse JM. Ubiquitin-Activated Interaction Traps (UBAITs) identify E3 ligase binding partners. EMBO Rep. 2015 Dec; 16(12):1699-712.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|